RKDA

$RKDA chatter on StockTwits

• 
  Rastox@epistox7h

  $RKDA it can be bought only in the range of .05 to .10...otherwise too expensive

  View on StockTwits ↗
• 
  dane wilkerson@Danjaftw1d

  $RKDA hello!

  View on StockTwits ↗
• 
  Beatrix William@beatrix19BullishAug 6

  $RKDA when 1$

  View on StockTwits ↗
• 
  Rastox@epistoxAug 6

  $RKDA remove your blindness...half of those shares can be issued without shareholders approval immediatelyat 0.91...!!!!

  View on StockTwits ↗
• 
  Jeremy Jacob@Jmoney914Aug 6

  $RKDA the 10 mil shares at .91 cannot be issued prior to shareholder approval. Annual meeting is on 9/10.

  View on StockTwits ↗
• 
  Rastox@epistoxAug 6

  $RKDA what premium??? nobody buys these pennies for a 20% return....that private placement has totally ruined all the story about this stock...above 0.91, there will be 10million more shares available here for sell, very despicable situation

  View on StockTwits ↗
• 
  Fractal_Trades@_Sensei_BullishAug 5

  $RKDA adding dips, amazing chart + $4M private placement priced at a premium

  View on StockTwits ↗
• 
  Rastox@epistoxAug 3

  $RKDA @Wohduhfok first learn some math and calculations, investing in RKDA at this price is equal to buying ABVE at 2.4$/share...... i have got some extra money , which i wanted to invest in ABVE to lower my average and currently we can do that just through RKDA....unfortunately nobody is ready to argue logically and answer my concerns....i m not left with any convincing argument to invest in RKDA...investing in RKDA at this price is equal to buying ABVE at 2.4$/share...

  View on StockTwits ↗
• 
  Send It@WokduhfokBullishAug 2

  $ABVEF $RKDA You're conflating two separate corporate events. $RKDA’s capital raise has nothing to do with $ABVE’s operational health or asset value. The facts: 1. Why RKDA Raised Capital: RKDA did that dilutive preferred offering (Series A-1/A-2) because Roosevelt Resources terminated their planned merger. When the deal fell through, RKDA had to raise emergency capital to secure its own cash runway. 2. No Impact on ABVE: RKDA’s short-term liquidity needs don't change the fundamental value of Above Food. RKDA holds ABVE shares as a legacy asset. A shareholder needing cash for separate operations has zero bearing on the business viability of the stock they hold. 3. The "Dead" Claim is Wrong: Saying ABVE is dead because RKDA had a merger fall through makes no sense. RKDA's balance sheet issues are isolated to RKDA.You're panicking over micro-cap raising capital because of a merger termination. Read the sec filing on the Roosevelt termination before you go spouting conspiracy.

  View on StockTwits ↗
• 
  cky1919@cky1919Aug 2

  $ABVEF $RKDA

  View on StockTwits ↗
• 
  Rastox@epistoxAug 2

  $ABVEF $RKDA @Tim442 serious question marks are present..... that say that almost certainly, the appeal is going to be rejected....and company will have to be relisted like a new one later on with r/s and $4/share price....

  View on StockTwits ↗
• 
  Rastox@epistoxAug 2

  $ABVEF $RKDA the biggest question mark has been created by RKDA actions (unless it has been done deliberately for insiders)....RKDA recently raised capital at 1.03$/share (around 3.8 million shares) with Extra Facility to same investors (at $0.91/share, around 7.7 million more shares) via two separate tranches of preferred investment options (Series A-1 and Series A-2).....that is a big question mark...if we assume a big prospect in ABVE , then these 'so called investors' will be free to sell around 12 million shares (paying first just around 0.91/share)......that demands a class action suit....or second scenario, ABVE is dead and we are doomed!!!

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 27

  Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 27

  Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 27

  Genvor, Inc. (OTCQB: $GNVR ), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.